Cargando…
Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
BACKGROUND: Gastric tumors are important gastrointestinal malignancies, and the prediction of therapeutic responses and related factors are important to improve the prognosis. Hence the aim of this study was to determine the therapeutic response to ramucirumab + folfiri in patients with metastatic g...
Autores principales: | Rezvani, Hamid, Haghighi, Shirin, Ghobakhlou, Mehdi, Ataei, Elnaz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731017/ https://www.ncbi.nlm.nih.gov/pubmed/36505597 http://dx.doi.org/10.4103/jfmpc.jfmpc_1678_21 |
Ejemplares similares
-
A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer
por: Masuishi, Toshiki, et al.
Publicado: (2022) -
Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
por: Masuishi, Toshiki, et al.
Publicado: (2023) -
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
por: Yasui, H., et al.
Publicado: (2023) -
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer
por: Roviello, Giandomenico, et al.
Publicado: (2018) -
The effect of the treatment of Helicobacter pylori infection on the glycemic control in type 2 diabetes mellitus
por: Zojaji, Homayon, et al.
Publicado: (2013)